- Home
- IMRN vs CODX Comparison
IMRN vs CODX Comparison
Compare IMRN & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- CODX
- Stock Information
- Founded
- IMRN 1994
- CODX 2013
- Country
- IMRN Australia
- CODX United States
- Employees
- IMRN N/A
- CODX N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- CODX Medical/Dental Instruments
- Sector
- IMRN Health Care
- CODX Health Care
- Exchange
- IMRN Nasdaq
- CODX Nasdaq
- Market Cap
- IMRN 9.2M
- CODX 9.8M
- IPO Year
- IMRN N/A
- CODX 2017
- Fundamental
- Price
- IMRN $1.88
- CODX $0.28
- Analyst Decision
- IMRN Strong Buy
- CODX Buy
- Analyst Count
- IMRN 1
- CODX 2
- Target Price
- IMRN $5.00
- CODX $5.50
- AVG Volume (30 Days)
- IMRN 25.2K
- CODX 462.7K
- Earning Date
- IMRN 07-07-2025
- CODX 08-07-2025
- Dividend Yield
- IMRN N/A
- CODX N/A
- EPS Growth
- IMRN N/A
- CODX N/A
- EPS
- IMRN N/A
- CODX N/A
- Revenue
- IMRN $4,048,286.00
- CODX $3,497,583.00
- Revenue This Year
- IMRN N/A
- CODX N/A
- Revenue Next Year
- IMRN N/A
- CODX $42.11
- P/E Ratio
- IMRN N/A
- CODX N/A
- Revenue Growth
- IMRN 82.90
- CODX N/A
- 52 Week Low
- IMRN $1.50
- CODX $0.23
- 52 Week High
- IMRN $2.87
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- IMRN 58.70
- CODX 43.19
- Support Level
- IMRN $1.68
- CODX $0.26
- Resistance Level
- IMRN $1.94
- CODX $0.29
- Average True Range (ATR)
- IMRN 0.09
- CODX 0.02
- MACD
- IMRN 0.02
- CODX 0.00
- Stochastic Oscillator
- IMRN 76.92
- CODX 26.83
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.